Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAD-US in Hemophilia A Patients: Low Dose Emicizumab vs. PK-Guided EHL FVIII
NCT07439055Phase 3Active, not recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Chulalongkorn University. Started Jun 2025; status: active, not recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07439055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439055.